Clinical Trial

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Trial Details
NCT Number NCT07625306
Lead Sponsor Novartis Pharmaceuticals
Conditions Acute Coronary Syndrome (ACS)
Enrollment 240 participants
Start Date 2026-08-31
Primary Completion 2028-12-07 (estimated)
Study Completion 2028-12-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-04